Skip Nav Destination
About this Journal
Journal Metrics
Impact Factor: 2.795 | |
CiteScore: 4.1 | |
Acceptance Rate: 46% | |
Time to final decision: 10 weeks |
News & Highlights
Gold Open Access Publication
All manuscripts submitted to the journal from September 15, 2022, and accepted for publication will carry the Open Access license CC BY-NC 4.0 or the license mandated by a funder. Upon acceptance, an Article Processing Charge (APC) will be levied.
New Editor-in-Chief: Rainer Straub
Learn more about the plans of Prof. Rainer Straub, the Editor-in-Chief of Neuroimmunomodulation, in the editorial: New Editor-in-Chief’s Note: The Past and the Future
Check Out Our Article Collections
Best of Neurodegenerative Diseases
Neuroinflammation in infectious Diseases
Neuroinflammation in Neurodegenerative and Psychiatric Diseases
Articles
Editor's Choice